tiprankstipranks
Trending News
More News >
CervoMed (CRVO)
NASDAQ:CRVO

CervoMed (CRVO) AI Stock Analysis

Compare
1,119 Followers

Top Page

CR

CervoMed

(NASDAQ:CRVO)

Rating:52Neutral
Price Target:
CervoMed's primary challenges stem from its lack of revenue and persistent financial losses, which heavily weigh down its stock score. However, positive technical indicators and recent promising clinical trial results provide a speculative upside, balancing some of the financial concerns. Valuation remains a challenge due to negative earnings, but the potential for future success in clinical trials offers hope for long-term growth.
Positive Factors
Clinical Trials
The high unmet need in dementia with Lewy bodies (DLB) could lead to a favorable decision from the FDA to proceed to Phase 3 clinical trials.
Financial Stability
Cervomed Inc. has a cash runway into mid-2026, providing some financial stability for ongoing and future trials.
Investor Confidence
CervoMed's latest data from the open label extension (OLE) study is boosting investor confidence, and a more risk-on approach is seen heading into the next steps for neflamapimod in dementia with Lewy bodies (DLB) patients.
Negative Factors
Capital Constraints
Capital constraints are a main challenge, with potential pressure on the stock if the FDA requires another randomized Phase 2 trial.
Funding Requirements
Cervomed Inc. will need to raise capital to conduct a Phase 3 program, with a modeled $25 million raise expected on the back of open-label extension data.
Market Conditions
A Phase 3 trial would require additional funding, and current volatile macro conditions present challenges for small/mid-cap biotech stocks like CRVO.

CervoMed (CRVO) vs. SPDR S&P 500 ETF (SPY)

CervoMed Business Overview & Revenue Model

Company DescriptionCervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
How the Company Makes MoneyCervoMed generates revenue primarily through the development and commercialization of its therapeutic products. The company invests heavily in research and development to create proprietary drugs and treatments, which are then patented and brought to market. Revenue streams include product sales, licensing agreements, and potential collaborations with larger pharmaceutical companies. These partnerships can provide upfront payments, milestone payments, and royalties on sales, contributing significantly to CervoMed's earnings. Additionally, the company may receive funding from grants and research institutions to support its development pipeline.

CervoMed Financial Statement Overview

Summary
CervoMed faces significant challenges in terms of revenue generation and profitability with consistent operational losses. While the balance sheet shows improved leverage metrics, the absence of revenue growth and persistent cash flow issues highlight the financial instability. The company's reliance on financing activities for liquidity further indicates ongoing financial risks.
Income Statement
12
Very Negative
CervoMed has shown a lack of revenue generation in recent years, with no revenue recorded in the latest periods and a significant decrease from the previous year. The company's gross profit margin is nonexistent due to zero revenues, and the net income remains negative, indicating continued losses. The EBIT and EBITDA margins are also negative, reflecting operational challenges and inefficiencies.
Balance Sheet
35
Negative
The company's balance sheet shows a positive equity position with a growing stockholders' equity, but this is overshadowed by historical high levels of debt and negative equity in prior years. The current debt position is improved with no total debt reported, leading to a lower leverage risk. However, persistent negative net income affects the return on equity.
Cash Flow
20
Very Negative
CervoMed has consistently negative operating cash flow, indicating cash outflows from regular operations. Despite the negative free cash flow over the years, the company has managed to maintain liquidity through significant financing activities. However, declining free cash flow growth poses a concern for future cash availability.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
3.29M9.74M7.14M0.000.000.00
Gross Profit
3.29M9.74M-1.29M-1.34M-93.42K-103.17K
EBIT
-20.94M-18.23M-7.81M-3.48M-16.04M-15.97M
EBITDA
-20.94M-18.23M-2.17M0.00-24.45M-15.76M
Net Income Common Stockholders
-18.67M-16.29M-2.17M-5.80M-24.10M-14.19M
Balance SheetCash, Cash Equivalents and Short-Term Investments
35.24M38.92M7.79M4.09M37.31M18.52M
Total Assets
38.58M43.08M9.97M4.16M37.84M29.55M
Total Debt
0.000.000.0036.70M10.03M149.16K
Net Debt
-10.50M-9.00M-7.79M32.61M-27.29M-18.37M
Total Liabilities
3.94M3.88M2.60M37.44M2.93M4.73M
Stockholders Equity
34.63M39.20M7.38M-33.29M34.91M24.81M
Cash FlowFree Cash Flow
-22.24M-16.53M-7.45M-2.57M-14.50M-13.55M
Operating Cash Flow
-22.24M-16.53M-7.45M-2.57M-14.50M-13.55M
Investing Cash Flow
-23.26M-28.66M0.00-12.24M4.00K0.00
Financing Cash Flow
46.40M46.40M11.15M0.0033.30M17.89M

CervoMed Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.47
Price Trends
50DMA
8.92
Negative
100DMA
6.52
Positive
200DMA
8.58
Negative
Market Momentum
MACD
-0.34
Positive
RSI
41.53
Neutral
STOCH
39.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVO, the sentiment is Negative. The current price of 7.47 is below the 20-day moving average (MA) of 8.04, below the 50-day MA of 8.92, and below the 200-day MA of 8.58, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 41.53 is Neutral, neither overbought nor oversold. The STOCH value of 39.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRVO.

CervoMed Risk Analysis

CervoMed disclosed 75 risk factors in its most recent earnings report. CervoMed reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CervoMed Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
52
Neutral
$67.18M-93.42%142.42%53.38%
49
Neutral
$112.42M-61.14%-100.00%-24.28%
43
Neutral
$79.20M-62.34%86.65%
41
Neutral
$92.58M-62.04%-61.95%
35
Underperform
$84.81M48.74%-1.60%
35
Underperform
$97.78M-54.64%1.27%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CRVO
CervoMed
7.47
-12.29
-62.20%
GALT
Galectin Therapeutics
1.32
-1.34
-50.38%
ANIX
Anixa Biosciences
3.42
0.70
25.74%
CLYM
Climb Bio
1.26
-7.43
-85.50%
ZURA
Zura Bio
1.26
-2.47
-66.22%
HLVX
HilleVax, Inc
1.96
-12.84
-86.76%

CervoMed Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
CervoMed Announces Executive Appointments and Changes
Neutral
Apr 18, 2025

CervoMed Inc. has announced significant executive appointments and changes effective in 2025. Kelly Blackburn has been promoted to Executive Vice President, Clinical Development, with an amended employment agreement detailing her compensation and severance provisions. Mark De Rosch has been appointed as Executive Vice President, Regulatory and Government Affairs and Program Management, with a comprehensive employment agreement outlining his salary and benefits. Additionally, the company has finalized a separation agreement with Chief Operating Officer Robert J. Cobuzzi, Jr., whose employment will conclude in July 2025, including provisions for severance pay and stock option vesting. These changes reflect CervoMed’s strategic adjustments in its leadership team, potentially impacting its operational focus and stakeholder interests.

Spark’s Take on CRVO Stock

According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.

CervoMed’s stock is weighed down by financial instability, marked by persistent losses and cash flow challenges. The recent positive clinical trial results offer a significant potential upside, but the speculative nature of these developments coupled with valuation challenges tempers the outlook. While technical indicators show some short-term momentum, the overall financial health remains a concern.

To see Spark’s full report on CRVO stock, click here.

Product-Related AnnouncementsBusiness Operations and Strategy
CervoMed Reports Positive Phase 2b Trial Results
Positive
Apr 7, 2025

On April 2, 2025, CervoMed announced positive clinical results from the first sixteen weeks of the open-label extension phase of their RewinD-LB Phase 2b clinical trial for neflamapimod, a treatment for dementia with Lewy bodies. The trial showed that neflamapimod slowed clinical progression and reduced falls compared to controls, with improvements in cognitive fluctuations and working memory. These findings, presented at the AD/PD 2025 conference, support the potential of neflamapimod as a transformative therapy for patients with dementia with Lewy bodies, and CervoMed plans to engage with regulatory authorities to finalize Phase 3 plans.

Spark’s Take on CRVO Stock

According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.

CervoMed’s stock score is primarily impacted by its financial challenges, with no revenue and persistent losses. However, technical indicators suggest positive momentum, and recent positive clinical trial results may improve future prospects. Valuation poses challenges due to negative earnings, but the potential for clinical success offers a speculative upside.

To see Spark’s full report on CRVO stock, click here.

Business Operations and StrategyFinancial Disclosures
CervoMed Shares Business and Financial Updates Online
Neutral
Mar 11, 2025

CervoMed has made available information about its business, clinical studies, development plans, and financial position on its website under the ‘Investors – Events and Presentations’ section. The company may use this information in various investor-related activities, but it does not commit to updating it publicly unless legally required.

Product-Related AnnouncementsBusiness Operations and Strategy
CervoMed Reports Positive Phase 2b Trial Results
Positive
Mar 10, 2025

On March 10, 2025, CervoMed Inc. announced positive results from the first 16 weeks of the extension phase of its Phase 2b RewinD-LB clinical trial for neflamapimod, aimed at treating dementia with Lewy bodies. The new batch of neflamapimod capsules showed improved plasma drug concentrations and significant improvements in clinical outcomes compared to old capsules and placebo, suggesting potential to alter the disease course. This development marks a significant step forward in the treatment of DLB, with the company planning to engage with regulatory authorities for Phase 3 trials.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.